4//SEC Filing
SV7 Impact Medicine Fund LP 4
Accession 0000899243-21-041838
CIK 0001840233other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 12:55 PM ET
Size
21.4 KB
Accession
0000899243-21-041838
Insider Transaction Report
Form 4
SV7 Impact Medicine Fund LP
10% Owner
Transactions
- Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total - Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total(indirect: See footnote)→ Common Stock (998,544 underlying) - Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total(indirect: See footnote)→ Common Stock (302,588 underlying) - Conversion
Common Stock
2021-10-26+998,544→ 998,544 total - Conversion
Common Stock
2021-10-26+998,544→ 998,544 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total→ Common Stock (998,544 underlying) - Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total→ Common Stock (302,588 underlying)
SV7 (IMF) GP LLP
10% Owner
Transactions
- Conversion
Common Stock
2021-10-26+998,544→ 998,544 total - Conversion
Common Stock
2021-10-26+998,544→ 998,544 total(indirect: See footnote) - Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total(indirect: See footnote)→ Common Stock (998,544 underlying) - Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total→ Common Stock (302,588 underlying) - Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total(indirect: See footnote)→ Common Stock (302,588 underlying) - Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total - Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total→ Common Stock (998,544 underlying)
Footnotes (3)
- [F1]The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
- [F2]Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
- [F3]Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
IncorporatedUnited Kingdom
Related Parties
1- filerCIK 0001780602
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 12:55 PM ET
- Size
- 21.4 KB